...A. We have, by the numbers, if you look at CRISPR, we have CASGEVY, which we're very proud of the approval of CASGEVY late last year together with our partners, Vertex and that's off to a great start in terms of commercial launch. B. But once we've established an operating model and once we see what the parlay is, that leads us to the next stage, which will be a $20-plus billion company where we're a fully integrated company and to have an engine that's producing -- continue to produce 1 or 2 INDs per year. C. So over the next 5 years, we expect that we'll announce at least 2 programs -- new programs a year, given the productivity of our scientific engine. D. Beyond CASGEVY, we have 3 additional franchises. E. We also are in solid tumors with our CTX130 program, which was a precursor to our current CTX131 program. F. And we showed nearly 70% editing in NHP studies in the liver, which equates to about 100% hepatocytes. G. ANGPTL3 is more for a rare disease type development approach and LPA...
